ABCDEFGHIJKLMNOPQRSTUVWXYZAAABACADAEAFAGAHAIAJAKALAM
1
Compulsory License TagCL Tag ProvisionDeal DateR&DClientLicensee CategoryDeal SourceDealUpfront Cash ($M)Deal Size ($M)Maximum Share (%)Equity ($M)Maximum Royalty (%)Deal TypeStageDeal SubjectExclusivityTerritoryDiseaseIndicationTechnologySub-TechnologyUpfront Equity ($M)Contingent Equity ($M)R&D Support ($M)FTE Rate ($M)Loan ($M)Dev / Reg Milestones ($M)Other Milestones ($M)Total Precommercial Payments ($M)Sales Milestones ($M)EFR$200M (%)EFR$500M (%)EFR$1B (%)Marketing Fee (%)Transfer Price (%)Manufacture Cost + (%)Profit Split (%)Financial Term Explanations
2
TagShare equivalent to PS percentage; CL not a sublicensee & CL rev not included in Net Sales10/2020Atea PharmaceuticalsRocheTop PharmaSEC RedactedDeal 350.00 1,000.00 Co-Development, LicensePhase IIAT-527 oral direct-acting antiviral to treat COVID-19 ex-USExclusiveAfrica, Asia, Europe, Middle East, NAFTA, South AmericaInfectious-ViralCoronavirusSyntheticsSmall Molecule 330.00 680.00 320.00
low double-digit to mid-twenties royalties, per Atea's IPO prospectus
3
TagShare equivalent to PS; CL rev not included in Net Sales7/2020Blueprint MedicinesRoche, GenentechMajor Biotech, Top PharmaSEC RedactedDeal 675.00 1,702.00 50.00 100.00 Co-Development, Co-Promotion, Equity, License, Option, SupplyPhase IPralsetinib RET inhibitor ex-China (co-exclusive rights in US), option to addt'l RET compoundExclusiveAfrica, Asia, Europe, Middle East, NAFTA, South AmericaCancerLung, Solid Tumors, Other CancerSyntheticsSmall Molecule 100.00 1,702.00 50.00
$100M equity investment priced at $96.57 per share | High teen to mid-twenties royalties in ROW, per Blueprint's 6Q20 | $927M in agg milestones, per Blueprint's 6Q20 | 50% PS in US
4
TagRoyalty reduced to CL rate7/2020Foghorn TherapeuticsMerckTop PharmaSEC RedactedDeal 15.00 425.00 Co-Development, License, ResearchDiscoveryGene Traffic Control platform to discover oncology therapeutics against transcription factor targetExclusiveWorldwideCancerBroad Focus CancerSyntheticsSmall Molecule 245.00 260.00 165.00
$165M per product, per Foghorn's IPO prospectus | mid-single digit to low teen royalties, per Foghorn's IPO prospectus | $245M per Foghorn's IPO prospectus
5
TagRoyalty reduced to CL rate5/2020Censa PharmaceuticalsPTC Therapeutics2013-20 IPOsSEC RedactedDeal 15.00 540.40 38.90 Acquisition, CVRPhase II, Orphan IndicationAcquisition for cash and sharesExclusiveWorldwideEndocrinological & Metabolic, Other/MiscellaneousGenetic Disorders, Other Endocrinological & MetabolicSyntheticsSmall Molecule 38.90 217.50 109.00 380.40 160.00
$160M, per PTC's 6Q20 | 845K PTC shares, per PTC's 6Q20 | Single-digit to low double-digit royalties, per PTC's 6Q20 | $217.5M for two lead products, including $30M on completion of Ph III enrollment for PKU, per PTC's 6Q20 | $109M for add'l indications, per PTC's 6Q20
6
TagShare equivalent to PS; CL not a sublicensee3/2020Silence TherapeuticsAstraZenecaTop PharmaSEC RedactedDeal 60.00 2,080.00 20.00 Co-Development, Equity, License, Option, ResearchDiscoveryRNAi therapeutics for cardio, renal, metabolic & respiratory diseasesExclusiveWorldwideCardiovascular, Endocrinological & Metabolic, Renal, RespiratoryBroad Focus Cardiovascular, Broad Focus Endocrinological & Metabolic, Broad Focus Renal, Broad Focus RespiratoryOligonucleotidesRNAi 20.00 150.00 600.00 830.00 1,250.00
$20M at signing, plus $40M by 1H21 | $250M/target | $20M for 4.2M shares, per Silence's IPO prospectus | high single-digit to low double-digit royalty, per Silence's IPO prospectus | $10M option exercise plus $140M dev/reg per target | $150M for each of 4 add'l targets
7
TagRoyalty reduced to co-excl or non-excl rate, as appropriate2/2020Queen’s UniversityTaysha Gene Therapies2013-20 IPOsSEC RedactedDeal 3.20 23.20 LicensePreclinicalTSHA-101 (bicistronic tansgene AAV9 vector) for GM2 gangliosidosisExclusiveWorldwideCentral Nervous System, Endocrinological & MetabolicLysosomal Storage Disorders, Other Central Nervous SystemOligonucleotidesGene Therapy 10.00 13.20 10.00
$10M, per Taysha's IPO prospectus | low single-digit royalties, per Taysha's IPO prospectus
8
TagRoyalty reduced to CL rate or to rate used to avoid a CL12/2019AbbVieAduro BioTech, Chinook Therapeutics2013-20 IPOsSEC RedactedDeal 141.70 6.70 Equity, LicensePhase IIIAtrasentan (endothelin receptor antagonist) for chronic kidney diseaseExclusiveWorldwideRenalBroad Focus RenalSyntheticsSmall Molecule 6.70 141.70
6.8M Chinook shares with FMV of $6.7M, per Aduro's 7/20 S-4 | upper single-digit to high-teen royalties, per Aduro's 7/20 S-4 | $135M in agg milestones, per Aduro's 7/20 S-4
9
TagRoyalty reduced to Generic Version rate, but not higher than CL rate12/2019Catalyst BiosciencesBiogenMajor BiotechSEC RedactedDeal 15.00 355.00 License, ResearchPreclinicalCB 2782-PEG (anti-C3 protease) to treat dry age-related macular degenerationExclusiveWorldwideOphthalmicAge-Related Macular DegenerationDrug DeliveryPEG Products 355.00
mid-single to low double-digit royalties, per Catalyst's 2019 10-K | $340M in agg milestones, per Catalyst's 2019 10-K
10
TagRoyalty reduced to Third Party Patent rate, max 50% reduction; CL rev not included in Net Sales12/2019PulmatrixJohnson & JohnsonTop PharmaSEC RedactedDeal 7.20 103.60 2.00 2.00 Co-Development, License, OptionPhase I, FormulationRV1162/PUR1800 (kinase inhibitors) with inhaled iSPERSE delivery for COPDExclusiveWorldwideCancer, RespiratoryChronic Obstructive Pulmonary Disease, LungDrug Delivery, SyntheticsOther, Small Molecule 3.40 48.00 58.60 45.00
$45M, per Pulmatrix' 2019 10-K | J&J pays $3.4M for tox study, per Pulmatrix' 2019 10-K; other dev cost pre-option are shared | 1-2% royalty, per Pulmatrix' 2019 10-K | $14M on option exercise, plus $34M in dev/reg milestones, per Pulmatrix' 2019 10-K
11
TagCL revenue not included in Net Sales12/2019Theravance BiopharmaPfizerTop PharmaSEC RedactedDeal 10.00 250.00 LicensePreclinicalTopically-applied skin-selective pan-JAK inhibitors for undisclosed skin conditionsExclusiveWorldwideDermatologicDrug Delivery, SyntheticsSmall Molecule, Topical 250.00
mid-single to low double-digit royalties, per Theravance's 3Q20 | $240M in agg milestones, per Theravance's 3Q20
12
TagRoyalty reduced to CL rate10/2019Blueprint MedicinesIpsen, Clementia PharmaceuticalsMid Tier Pharma, 2013-20 IPOsSEC RedactedDeal 25.00 535.00 LicensePhase I, Orphan IndicationBLU-782 (ALK2 inhibitor) for fibrodysplasia ossificans progressivaExclusiveWorldwideOther/MiscellaneousGenetic DisordersSyntheticsSmall Molecule 535.00
low- to mid-teen royalty, per Blueprint's 9Q19 | $510M in agg milestones, per Blueprint's 9Q19
13
TagShare equivalent to PS; CL rev not included in Net Sales10/2019Dicerna PharmaceuticalsRocheTop PharmaSEC RedactedDeal 200.00 1,670.00 Co-Development, Co-Promotion, License, Option, ResearchPhase I, DiscoveryRG6346 (DCR-HBVS) for hepatitis BExclusiveWorldwideInfectious-ViralHepatitis BOligonucleotidesRNAi 1,670.00
up to mid-teen royalties; Dicerna has option to co-fund pivotal trials, for 20s-30s US royalties and US co-promotion rights, per Dicerna's 2019 10-K | $1.47B in agg milestones, per Dicerna's 2019 10-K
14
TagRoyalty reduced to CON % of CL rate9/2019ChimerixSymBio PharmaceuticalsSEC RedactedDeal 5.00 185.00 LicensePreclinicalBCV (brincidofovir) for all indications except smallpoxExclusiveWorldwideInfectious-ViralBroad Focus Infectious-Viral 185.00
low double-digit royalty, per Chimerix's 2019 10-K | $180M in agg milestones, per Chimerix's 2019 10-K
15
TagRoyalty reduced to CL rate or to rate used to avoid a CL9/2019KemPharmGurnet Point, Boston PharmaceuticalsSEC RedactedDeal 10.00 493.00 Co-Development, License, OptionPhase III, PreclinicalKP415 and KP484 SDX and d-MPH products for ADHD, option to KP879 and KP922ExclusiveWorldwidePsychiatricAttention Deficit Hyperactivity DisorderSyntheticsSmall Molecule 63.00 73.00 420.00
Royalties ranging from high single digits to mid-twenties in the US and low to mid-single digits in ex-US countries, per KemPharm's 9/4/19 8-K | $63M, per KemPharm's 9/4/19 8-K | Boston reimburses 3rd party costs only
16
TagRoyalty reduced to CL rate7/2019Jounce TherapeuticsBristol-Myers Squibb, CelgeneMajor Biotech, Top PharmaSEC RedactedDeal 50.00 530.00 License, RestatementPreclinicalJTX-8064 anti-Leukocyte Immunoglobulin Like Receptor B2 (LILRB2) antibody for cancerExclusiveWorldwideCancerBroad Focus CancerMonoclonals 180.00 230.00 300.00
mid single-digit to low double-digit royalties, per Jounce's 2019 10-K
17
TagRoyalty reduced to CL rate6/2019ArvinasBayerTop PharmaSEC RedactedDeal 17.50 749.50 32.50 Equity, License, ResearchDiscoveryPROTAC protein degrader technology for cardiovascular, oncology and gynecologic diseasesExclusiveWorldwideCancer, Cardiovascular, Genitourinary/GynecologicBroad Focus Cancer, Broad Focus Cardiovascular, Broad Focus Genitourinary/GynecologicSyntheticsSmall Molecule 32.50 12.00 197.50 259.50 490.00
$490M, per Arvinas' 3Q20 | $12M R&D funding thru 2022, per Arvinas' 3Q20 | Mid-single to low double-digit royalties, per Arvinas' 3Q20 | $197.5M, per Arvinas' 3Q20 | $32.5M at 115% of FMV
18
TagRoyalty reduced to CON % of CL rate; CL not a sublicensee & CL rev not included in Net Sales12/2018Proteostasis TherapeuticsRoche, GenentechMajor Biotech, Top PharmaSEC RedactedDeal 5.00 101.00 LicenseSmall molecule modulators for undisclosed targetExclusiveWorldwideSyntheticsSmall Molecule 101.00
low single-digit royalties, per Proteostasis' 2018 10-K | $96M in agg milestones, per Proteostasis' 2018 10-K
19
TagRoyalty reduced to CL rate11/2018ZymeworksBeiGene2013-20 IPOsSEC RedactedDeal 20.00 722.00 License, ResearchDiscoveryAzymetric and EFECT platforms for up to three bispecific antibodies for BeiGene selected targetsExclusiveWorldwideUnlimitedMonoclonalsBispecific 722.00
$20M for Azymetric and EFECT agreement | $702M in development and commercial milestones for up to three bispecific product candidates under platform agreement.
20
TagEquitable royalty reduction to be negotiated after CL in such country10/2018Arrowhead PharmaceuticalsJohnson & Johnson, JanssenTop PharmaSEC RedactedDeal 175.00 3,750.00 75.00 Equity, License, Option, ResearchPhase I, DiscoveryARO-HBV for hepatitis B and option for up to three additional RNAi therapeuticsExclusiveWorldwideInfectious-ViralHepatitis BOligonucleotidesRNAi 75.00 3,750.00
3.26M common shares @ $23/sh | royalties to mid-teens under ARO-HBV license, and to low-teens under research collaboration, per Arrowhead's 12Q18 | $1.6B in agg milestones for ARO-HBV, plus $1.9M for three add'l targets, per Arrowhead's 12Q18
21
TagCL revenue not included in Net Sales10/2018CollplantUnited Therapeutics, Lung BiotechnologySEC RedactedDeal 5.00 44.00 License, Option, SupplyLead MoleculehCollagen-based BioInk for 3D bioprinted lung transplants with option to 3 additional organsExclusiveWorldwideTransplantationOrgan/Tissue TransplantsCollagen matrix, Recombinant DNA 15.00 24.00 44.00
Option exercise payments up to $9 million, $15M in additional development milestones for other manufactured organs
22
TagRoyalty reduced to CON % of CL rate; CL not a sublicensee & CL rev not included in Net Sales10/2018SQZ BiotechRocheTop PharmaSEC RedactedDeal 45.00 1,702.00 50.00 Co-Development, Co-Promotion, License, Option, ResearchPreclinical, DiscoveryMononuclear antigen presenting cells via HPV and tumor cell lycate (TCL) for oncologyExclusiveWorldwideCancer, Infectious-ViralBroad Focus Cancer, Other Infectious-Viral
Cell Therapy - Stem Cells/Factors, Transgenics
457.00 502.00 1,200.00 50.00
$45M | $1.2B, per SQZ's IPO prospectus | mid double-digit reimb of dev costs, per SQZ's IPO prospectus | mid-single digit to mid-teen royalties | $217M in dev plus $240M in reg milestones, per SQZ's IPO prospectus | 50% PS in US for TCL Products, per SQZ's IPO prospectus
23
TagRoyalty reduced to CON %; same for Generic Sublicensee9/2018Precision BioSciencesGileadMajor BiotechSEC RedactedDeal 485.00 License, Research, TerminationDiscoveryARCUS genome editing platform to develop HBV therapiesExclusiveWorldwideInfectious-ViralHepatitis BCell Therapy - Stem Cells/Factors 40.00 105.00 145.00 340.00
$340M, per Precision's IPO prospectus | $40M in research funding, per Precision's IPO prospectus | high single-digit to mid-teen royalties, per Precision's IPO prospectus | $105M, per Precision's IPO prospectus
24
TagRoyalty reduced by same % as Market Share Loss w CON % floor & carryforward; same for comp product 8/2018Ionis Pharmaceuticals, Akcea TherapeuticsPTC Therapeutics2013-20 IPOsSEC RedactedDeal 12.00 26.00 License, SupplyFiled, Orphan IndicationTegsedi (inotersen) and Waylivra (volanesorsen) for orphan neuro and metabolic diseases in SAExclusiveNAFTA, South AmericaCentral Nervous System, Endocrinological & MetabolicOther Central Nervous System, Other Endocrinological & MetabolicOligonucleotidesAntisense/Triple helix 4.00 10.00 26.00
$12M upfront for Tegsedi, per PTC's 9Q18 | mid-twenties royalties, per Akcea's 9Q18 | $4M on Brazil approval of Tegsedi, per PTC's 9Q18 | $6M on Waylivra FDA or EMA approval, plus $4M on Brazil approval, per PTC's 9Q18
25
TagRoyalty reduced to CL rate7/2018Sutro BiopharmaMerckTop PharmaSEC RedactedDeal 60.00 1,690.00 30.00 Equity, License, Option, Research, SupplyDiscoveryCell-free protein synthesis & site-specific conjugation platform for cancer & autoimmune diseasesExclusiveWorldwideAutoimmune/Inflammatory, CancerBroad Focus Autoimmune/Inflammatory, Broad Focus CancerMonoclonalsConjugates 20.00 10.00 1,690.00
$10M at IPO, per Sutro's IPO prospectus | Mid-single digit to low teen royalties, per Sutro's IPO prospectus | $1.6B in agg milestones, per Sutro's IPO prospectus
26
TagCL revenue not included in Net Sales; minimum royalties to be renegotiated if CL or generic competition5/2018LipimetiXAnji PharmaceuticalsSEC FullDealSublicenseApo E mimetic peptide platform including AEM-28 and analogs in ChinaExclusiveAsiaPeptides
27
TagRoyalty reduced to CL rate4/2018Children's Hospital of Philadelphia, University of PennsylvaniaCabaletta Bio2013-20 IPOsSEC RedactedDeal 29.70 1.20 Equity, License, ResearchPreclinical, Orphan IndicationDSG3-CAART therapy for B cell-mediated autoimmune diseasesExclusiveWorldwideAutoimmune/InflammatoryOther Autoimmune/InflammatoryCell Therapy - Stem Cells/Factors 1.20 8.50 29.70
$8.5M over 3 yrs | low single digit royalty, per Cabaletta's IPO prospectus | $20M in agg milestones, per Cabaletta's IPO prospectus | 481K common shares, with FMV of $1.2M, per Cabaletta's IPO prospectus
28
TagIf CL rate is below 3rd Party Patent or Biosimilar rate, then 50% sharing2/2017AdimabX4 Pharmaceuticals, Arsanis2013-20 IPOsFOIADeal 24.76 4.00 4.00 License, Option, ResearchLead MoleculeRSV antibody programExclusiveWorldwideInfectious-ViralRespiratory Syncytial Virus/RSVMonoclonalsHuman Abs 0.33 16.50 8.13 24.63 4.00 4.00 4.00
29
TagCL royalty reduced to "such rate as would be reasonable"4/2016Lantheus Medical Imaging, Progenics PharmaceuticalsBayerTop PharmaFOIADeal 4.00 183.00 5.00 LicenseLead MoleculePSMA antibody Conjugated with targeted thorium for prostate cancerExclusiveWorldwideCancerProstateMonoclonalsConjugates, Human Abs 49.00 53.00 130.00 3.00 3.00 4.00
30
TagRoyalty reduced to CL rate, with add'l adjustments for 3rd Party Patents1/2016MacrolideMelinta Therapeutics, Cempra2003-12 IPOsFOIADeal 0.75 5.25 1.00 1.00 License, Option, Research, TerminationLead MoleculeMethods of synthesizing solithromycin ex-AseanExclusiveAfrica, Asia, Europe, Middle East, NAFTA, South AmericaInfectious-BacterialBroad Focus Infectious-Bacterial 1.50 2.00 4.25 1.00 1.00 1.00 1.00 $1.5M over 18 months
31
TagRoyalty reduced to CL rate2/2015University of PennsylvaniaAllergan, AbbVie, Kythera BiopharmaceuticalsTop Pharma, Mid Tier Pharma, 2003-12 IPOsFOIADeal 0.22 4.34 4.00 4.00 LicensePreclinicalIP covering use of PGD2 receptor antagonists for hair lossExclusiveWorldwideOther/MiscellaneousHair GrowthSyntheticsSmall Molecule 0.88 0.25 1.34 3.00 2.00 2.00 3.00
32
TagRoyalty reduced to 50% of CL rate, plus 50% of any add'l CL payments; max royalty reduction of 75%2/2014ArdelyxSanofiTop PharmaFOIADeal 1.25 198.00 11.00 11.00 Co-Promotion, Development, License, Option, TerminationPreclinicalNaP2b phosphate transport inhibitor for kidney diseaseExclusiveWorldwideRenalKidney Stones, Other RenalSyntheticsSmall Molecule 0.25 196.75 198.00 6.00 7.00 9.00 $10M on option exercise, plus $186.75M in dev/reg milestones
33
TagRoyalty reduced to CL rate12/2013BioVascularGalena Biopharma, Sellas Life Sciences Group, Mills PharmaceuticalsFOIADeal 0.10 13.90 6.00 6.00 LicensePhase I, FormulationCR formulation of anagrelide for cancer & cardioExclusiveWorldwideCancer, CardiovascularLeukemia, Myocardial InfarctionDrug DeliveryControlled Release 6.85 6.95 13.90 5.00 6.00 6.00 $6.95M for Cardio Field
34
TagCRE to oppose CL; royalty reduced to CL rate or to rate used to avoid a CL2/2013Acer Therapeutics, Opexa TherapeuticsMerck KGaA, Merck SeronoTop PharmaFOIADeal 5.00 225.00 18.00 18.00 Co-Development, License, Option, SupplyPhase II, Orphan IndicationTcelna (imilecleucel-T) autologous T-cell therapy for multiple sclerosis ex-JapanExclusiveAfrica, Asia, Europe, Middle East, NAFTA, South AmericaCentral Nervous SystemMultiple SclerosisCell Therapy - Stem Cells/Factors, Vaccines 0.30 95.00 40.00 140.00 85.00 8.00 8.00 9.00
$5M option fee | 8-15% royalty, increased to 10-18% if Opexa pays 33% of 1st indication | $25M option exercise, plus $70M dev/reg 1st | $40M for relapsing remitting MS indication
35
TagCRE to oppose CL; royalty reduced to CL rate plus 50% of any add'l CL payments; max royalty reduction of 50% w carryforward10/2012ArdelyxAstraZenecaTop PharmaFOIADeal 35.00 860.00 20.00 20.00 Co-Development, Co-Promotion, Development, License, Option, TerminationPhase IITenapanor (RDX5791 NHE3 inhibitor) for IBS-C, end stage renal & kidney diseaseExclusiveWorldwideGastrointestinal, RenalIBD - Other, Nephritis - Other, Other RenalSyntheticsSmall Molecule 0.25 215.00 250.00 500.00 360.00 9.00 9.00 11.00
9-17% royalty, plus 1-3% add'l if Ardelyx funds $20-40M of Ph III trials | $215M for constipation-related indication
36
TagCRE to oppose CL; royalty reduced to CL rate7/2012Georgia Tech, Emory UniversityClearside Biomedical2013-20 IPOsFOIADeal 0.14 0.25 3.00 3.00 LicenseDeviceMicroneedle for ocular procedure and tissue injectionsExclusiveWorldwideOphthalmicBroad Focus OphthalmicDrug DeliveryOther 0.11 0.25 3.00 3.00 3.00
37
TagRoyalty reduced to CL rate4/2012Novartis, EndocyteMerckTop PharmaFOIADeal 120.00 1,001.50 50.00 20.00 Co-Development, Co-Promotion, License, Option, TerminationPhase IIIVintafolide (EC145) folate conjugate for lung & ovarian cancerExclusiveWorldwideCancerLung, OvarianSyntheticsSmall Molecule 0.25 47.50 334.00 501.50 500.00 14.00 14.00 15.00 50.00
Endocyte pays 75% of PROC (ovarian) Ph III plus 100% of Companion Diagnostic; Merck pays all other dev costs | 14-20% ex-US royalty | $47.5M for Ovarian (PROC) | $60M for Lung; $274N for Other Indications | 50% PS in US
38
TagRoyalty reduced to CL rate9/2011Children’s Cancer Institute AustraliaCleveland BioLabs, Panacela Labs2003-12 IPOsFOIADeal 6.50 2.00 2.00 Equity, License, OptionPreclinicalSmall Molecules Inhibiting Oncoprotein MYC for solid tumor treatmentExclusiveWorldwideCancerSolid TumorsSyntheticsSmall Molecule 6.50 6.50 2.00 2.00 2.00 2% of OS shares at signing
39
TagRoyalty reduced to CL rate9/2011Roswell Park Cancer Institute, Health Research IncCleveland BioLabs, Panacela Labs2003-12 IPOsFOIADeal 0.02 3.20 1.00 1.00 Equity, License, Option, ResearchPreclinical, Lead MoleculeCuraxin CBL0137, TLR-5 agonist & MYC inhibitor for treatment of cancerExclusiveWorldwideCancerBroad Focus Cancer 0.85 2.33 3.20 1.00 1.00 1.00
$24.8K for patent costs | 1656 common shares | 1% royalty (3% if sold before FDA approval)
40
TagRoyalty reduced to CL rate5/2011AdimabX4 Pharmaceuticals, Arsanis2013-20 IPOsFOIADeal 0.05 1.20 6.00 6.00 License, Option, ResearchDiscoveryYeast monoclonals against bacterial lipopolysaccharide (LPS) targetsExclusiveWorldwideInfectious-BacterialBroad Focus Infectious-BacterialMonoclonalsHuman Abs 1.10 0.28 1.20 6.00 6.00 6.00 Min 4 FTEs @ $280K/FTE for 1 yr
41
Tag50% of Net Sales disregarded in country w CL; max royalty reduction of 50% w carryforward12/2009Catalyst Biosciences, TargaceptAstraZenecaTop PharmaFOIADeal 200.00 1,240.00 25.00 25.00 Co-Development, Co-Promotion, License, Option, Research, TerminationPhase IIAmplixa (TC-5214 nicotinic channel blocker) for major depressive disorderExclusiveWorldwidePsychiatricDepression & ManiaSyntheticsSmall Molecule 0.25 285.00 255.00 740.00 500.00 20.00 21.00 23.00
20% in US; 16% in ROW | 21% in US; 17% in ROW | 22.5% in US; 18.5% in ROW | 25% max US royalty; 22% in ROW | $285M for adjunct therapy | $255M for monotherapy
42
TagRoyalty reduced to CL rate w add'l adjustment for Generic Competition12/2009Daiichi Sankyo, Ambit BiosciencesAstellas PharmaTop Pharma, Japanese PharmaFOIADeal 40.00 355.00 50.00 22.00 Co-Development, Co-Promotion, License, Research, TerminationPhase IIAC220 (quizartinib FLT3 kinase inhibitor) for acute myeloid leukemiaExclusiveWorldwideCancerLeukemiaSyntheticsSmall Molecule 0.29 140.00 170.00 350.00 5.00 12.00 15.00 19.00 50.00
12-22% ex-US royalty | $140M for AML | $100M for add'l oncology, plus $70M for non-oncology indications | 50/50 PS in US if co-promote
43
TagRoyalty reduced to CL rate, but with 1% royalty floor12/2009Ionis PharmaceuticalsLillyTop PharmaFOIADeal 105.00 10.00 10.00 Co-Development, License, OptionPhase IEukaryotic initiation factor 4E (LLY2275796 eIF-4E antisense compound) for cancerExclusiveWorldwideCancerColorectalOligonucleotidesAntisense/Triple helix 55.00 50.00 105.00 5.00 5.00 7.00 $30-50M on license option exercise
44
TagRoyalty reduced to CL rate w add'l adjustment for Generic Competition12/2008Actavis, Allergan, AbbVie, MAP PharmaceuticalsAstraZenecaTop PharmaFOIADeal 40.00 900.00 30.00 30.00 Co-Promotion, Development, LicensePhase III, FormulationUnit Dose Budesonide for pediatric asthmaExclusiveWorldwideRespiratoryAsthmaDrug DeliveryNasal 0.35 290.00 55.00 385.00 515.00 19.00 19.00 19.00 30% US max rate; 20% ROW max rate
45
TagRoyalty reduced to CL rate12/2008LigandGlaxoSmithKlineTop PharmaFOIADeal 5.00 163.00 16.00 16.00 LicensePhase II, Orphan IndicationLGD-4665 thrombopoietin mimetic for treatment of thrombocytopeniaExclusiveWorldwideHematologicThrombocytopeniaSyntheticsSmall Molecule 83.00 88.00 75.00 16.00 16.00 16.00 8% for first yr, then 16% thereafter
46
TagNet Sales in country w CL calculated on basis of CL royalty only10/2008LpathMerck KGaA, Merck SeronoTop PharmaFOIADeal 4.00 467.50 15.00 15.00 Development, LicensePhase ISonepcizumab ( sphingosine-I-phosphate antibody) for solid tumors & MSExclusiveWorldwideCancer, Central Nervous SystemMultiple Sclerosis, Solid TumorsMonoclonalsHumanized Abs 6.00 92.50 322.00 424.50 43.00 7.00 7.00 9.00 $500K/month for 1 yr
47
TagRoyalty reduced to 50% of CL rate, plus 50% of any add'l CL payments12/2007Idera PharmaceuticalsMerck Serono, Merck KGaATop PharmaFOIADeal 40.00 431.40 13.00 13.00 Development, License, TerminationPhase II, PreclinicalIMO-2055 and IMO-2125 (TLR9 agonists) for the treatment of cancer excluding vaccinesExclusiveWorldwideCancerBroad Focus CancerOligonucleotidesAntisense/Triple helix 0.70 57.70 288.60 387.00 44.40 5.00 5.00 6.00 $700K reimb for current trials
48
TagRoyalty reduced to CL rate12/2007University of British ColumbiaQLTFOIADeal 0.05 0.05 2.00 2.00 License, RestatementApprovedVisudyne (beverteportin) photodynamic therapyExclusiveWorldwideOphthalmicAge-Related Macular DegenerationPhototherapy 0.05 2.00 2.00 2.00 Cdn$5K AMF plus $30K legal costs
49
TagRoyalty reduced to CL rate11/2007Oncternal Therapeutics, GTxMerckTop PharmaFOIADeal 40.00 592.00 23.00 30.00 23.00 Co-Development, Co-Promotion, Equity, License, Research, Termination
Phase II, Preclinical, Lead Molecule
Ostarine (selective androgen receptor modulator) for cancer-related muscle lossExclusiveWorldwideCancer, Endocrinological & MetabolicOther Cancer, Other Endocrinological & MetabolicSyntheticsSmall Molecule 30.00 15.00 60.00 447.00 592.00 13.00 13.00 13.00
1.285M common shares @ $23.34/sh (see Equity agmt) | $5M in R&D funding/yr for 3 yrs | $60M for Ostarine for Cancer Cachexia | $220M for sarcopenia; $142M add'l for cancer cachexia; $85M for any other indication
50
TagRoyalty reduced to CL rate w add'l adjustment for 3rd Party Patents10/2007BayerMidatech, Dara Biosciences1991-2001 IPOsFOIADeal 0.60 16.35 14.00 14.00 LicensePreclinicalPPAR compounds (including Bay62-9069) for Type 2 diabetes & dyslipidemiaExclusiveWorldwideEndocrinological & MetabolicDiabetesSyntheticsSmall Molecule 10.50 5.25 16.35 11.00 12.00 12.00 $10.5M for Type 2 diabetes
51
TagRoyalty reduced to CL rate9/2007Akebia Therapeutics, Keryx BiopharmaceuticalsJapan Tobacco, Torii PharmaceuticalJapanese PharmaFOIADeal 20.00 100.00 14.00 14.00 LicensePhase IIAuryxia/Riona (ferric citrate) for hyperphosphatemia in JapanExclusiveAsiaEndocrinological & Metabolic, RenalOther Endocrinological & Metabolic, Other RenalSyntheticsSmall Molecule 25.00 45.00 55.00 11.00 13.00 14.00
52
TagRoyalty reduced to CL rate9/2007Dainippon Sumitomo, Sunovion PharmaceuticalsGlaxoSmithKlineTop PharmaFOIADeal 20.00 155.00 23.00 23.00 Distribution, License, TerminationFiledLunivia (eszopiclone) for treatment of insomnia ex-NAFTA and JapanExclusiveAfrica, Asia, Europe, Middle East, South AmericaCentral Nervous SystemSleep DisordersDrug DeliveryOral 45.00 65.00 90.00 14.00 19.00 21.00 25.00
53
TagIf CL granted, parties will consult and cooperate to be competitive8/2007AradigmUnited Therapeutics, Lung BiotechnologyFOIADeal 0.88 14.00 10.00 3.47 10.00 Co-Development, Equity, LicensePhase II, FormulationTyvaso (AERx pulmonary delivery of treprostinil) for arterial hypertensionExclusiveWorldwideCardiovascularHypertensionDrug DeliveryNasal 3.47 9.65 14.00 9.00 7.00 5.00
54
TagRoyalty reduced to CL rate6/2007SurModicsMerckTop PharmaFOIADeal 20.00 207.50 9.00 9.00 Development, License, Supply, Termination
Phase I, Lead Molecule, Formulation
I-vation SR delivery of triamcinolone acetonide and KDR kinase inhibitors for macular edema & AMDExclusiveWorldwideOphthalmicBroad Focus Ophthalmic, Age-Related Macular DegenerationDrug DeliverySustained Release 3.50 78.00 106.00 207.50 9.00 9.00 9.00 65.00
9% for TA Product; 4-8% for KDR Product or Other Target(s) | SurModic's Profit of 65% over Economic Cost (see Supply agmt)
55
TagNet Sales in country w CL calculated on basis of CL royalty only5/2007Transcept Pharmaceuticals, Paratek Pharmaceuticals, NovaceaMerck, Schering-PloughTop PharmaFOIADeal 60.00 452.00 24.00 12.00 24.00 Co-Promotion, Development, Equity, License, TerminationPhase IIIAsentar (DN-101 oral calcitriol) for prostate cancerExclusiveWorldwideCancerProstateSyntheticsSmall Molecule 12.00 0.25 50.00 330.00 452.00 18.00 19.00 21.00
56
TagRoyalty reduced to CL rate5/2007University of MaastrichtBG Medicine Inc.2003-12 IPOsFOIADeal 0.75 2.00 2.00 Development, LicenseDiagnosticBiomarker-based molecular diagnostic test as a prognostic indicator of congestive heart failureExclusiveWorldwideCardiovascularCongestive Heart FailureDiagnostics 0.75 0.75 2.00 2.00 2.00
57
TagRoyalty reduced to CL rate4/2007Pfizer, Coley PharmaceuticalMerckTop PharmaFOIADeal 4.00 15.50 4.00 4.00 LicenseLead MoleculeVaxImmune adjuvant for use in vaccinesNon-exclusiveWorldwideInfectious-ViralBroad Focus Infectious-ViralAdjuvant, Vaccines 11.00 0.50 15.50 4.00 4.00 4.00
58
TagRoyalty reduced to CL rate3/2007Clinical Data, Avalon PharmaceuticalsMerckTop PharmaFOIADeal 202.00 10.00 10.00 Co-Development, License, ResearchDiscoveryAvalonRx platform to screen compounds for STAT3 inhibitors to treat cancerExclusiveWorldwideCancerBroad Focus CancerScreening 108.00 64.00 172.00 30.00 8.00 8.00 9.00
59
TagRoyalty reduced to CL rate w add'l adjustment for 3rd Party Patents3/2007SLA PharmaAssembly BioSciencesFOIADeal 0.25 26.50 8.00 8.00 Development, Equity, LicensePhase II, FormulationAnoheal (topical diltiazem) & Incostop (topical phenylephrine) for pain from anal fissuresExclusiveNAFTAGenitourinary/GynecologicOther Genitourinary/GynecologicDrug DeliveryTopical 6.00 7.13 13.13 26.50 7.00 8.00 8.00
5% of OS shares of Licensee | $83K/month for 2 yrs plus $4M for EU clinical costs | $7.125M for Anoheal | $13.125 for Incostop
60
TagRoyalty reduced to CL rate2/2007GW PharmaceuticalsOtsuka PharmaceuticalTop Pharma, Japanese PharmaFOIADeal 18.00 303.70 25.00 5.00 Development, License, Supply, TerminationPhase III, Orphan IndicationSativex (cannabis-based medicinal extract) for MS, neuopathic and cancer pain in USExclusiveNAFTACancer, Central Nervous SystemBroad Focus Cancer, Multiple Sclerosis, PainNatural Product 30.70 25.00 30.00 103.70 200.00 20.00 $30.7M for 1st indication | 5% royalty (plus transfer price)
61
TagRoyalty reduced to CL rate12/2006Idera PharmaceuticalsMerckTop PharmaFOIADeal 20.00 455.00 10.00 8.00 Equity, License, ResearchDiscoveryToll-­like Receptor (TLR) agonists for cancer, infection & Alzheimers vaccinesExclusiveWorldwideCancer, Central Nervous System, Infectious-ViralBroad Focus Cancer, Broad Focus Infectious-Viral, Alzheimer's DiseaseOligonucleotides, VaccinesLigands 10.00 5.00 60.00 185.00 280.00 5.00 5.00 6.00 $60M for Alzheimer's
62
TagRoyalty reduced to CL rate12/2006NuadaMidatech, Dara Biosciences1991-2001 IPOsFOIADeal 0.01 6.00 3.00 3.00 LicenseLead MoleculePeptidase inhibitorsExclusiveWorldwideUnlimitedPeptides 5.95 6.00 3.00 3.00 3.00
63
TagRoyalty reduced to CL rate10/2006InterMuneRocheTop PharmaFOIADeal 60.00 560.00 19.00 19.00 Co-Development, Co-Promotion, License, TerminationPreclinicalDanoprevir (ITMN-191) cyclic macrocycle for HCVExclusiveWorldwideInfectious-ViralHepatitis CPeptides 250.00 310.00 240.00 14.00 15.00 17.00 50.00
64
TagCRE to oppose CL; royalty reduced to CL rate, except no royalty on Product provided at or below cost in crisis10/2006Ligand, Metabasis TherapeuticsMerck, Idenix PharmaceuticalsTop Pharma, 2003-12 IPOsFOIADeal 2.00 68.80 9.00 9.00 Development, License, ResearchDiscoveryHepDirect liver-targeting technology for HCVExclusiveWorldwideInfectious-ViralHepatitis CDrug Delivery, Screening, SyntheticsOther, Small Molecule 3.30 0.28 63.50 68.80 6.00 7.00 8.00
65
TagRoyalty reduced to CL rate10/2006Meiji SeikaMediciNova2003-12 IPOsFOIADeal 0.40 9.05 9.00 9.00 LicenseLead MoleculeCP4715 (alphaVbeta3 / GPIIb/IIIa receptor dual antag) for cardio ex-Japan, China, Korea & ASEANExclusiveAfrica, Asia, Europe, Middle East, NAFTA, South AmericaCardiovascularBroad Focus CardiovascularSyntheticsSmall Molecule 8.65 9.05 5.00 7.00 8.00 5-7% in US & 5-7% in ROW
66
TagRoyalty reduced to CL rate10/2006Meiji SeikaMediciNova2003-12 IPOsFOIADeal 0.40 9.05 9.00 9.00 LicenseLead MoleculeEF6265 (fibrinolysis inhibitor) & EF6243 antithrombotic for cardio ex-Japan, China, Korea & ASEANExclusiveAfrica, Asia, Europe, Middle East, NAFTA, South AmericaCardiovascularBroad Focus CardiovascularSyntheticsSmall Molecule 8.65 9.05 5.00 7.00 8.00 5-9% in US & 5-7% in ROW
67
TagRoyalty reduced to CL rate8/2006Adare Pharmaceuticals, EurandOtsuka Pharmaceutical, Avanir PharmaceuticalsTop Pharma, Japanese PharmaFOIADeal 0.10 23.20 5.00 5.00 Development, LicensePreclinical, FormulationDiffucaps CR formulation of ZENVIA for painExclusiveWorldwideCentral Nervous SystemPainDrug DeliveryControlled Release 1.58 5.00 6.68 14.00 5.00 5.00 5.00
68
TagRoyalty reduced to CL rate7/2006AlnylamMerckTop PharmaFOIADeal 84.50 50.00 15.00 Co-Development, Co-Promotion, License, Option, Research, Restatement, TerminationDiscoveryRNAi for nine non-druggable targetsExclusiveWorldwideUnlimitedOligonucleotidesRNAi 0.49 41.00 43.50 84.50 10.00 12.00 13.00 50.00
10-15% ROW royalty for RNAi Products; 5-10% on Merck Development Products | $30.5M for Opt-out RNAi Product; $5.5M for Profit Sharing RNAi Product; $7.5M on Merck's Opt-in for RHOA Product | 50/50 PS on Profit Sharing RNAi Products in US | $41M for Merck Development Products
69
TagCRE to oppose CL; if CL only distributes, country Net Sales based on all CL payments; if CL supplies, royalty is 20% of all CL payments6/2006Adhera TherapeuticsBristol-Myers Squibb, AmylinTop Pharma, 1991-2001 IPOsFOIADeal 89.00 9.00 9.00 Development, License, SupplyPreclinical, FormulationIntranasal delivery of Exenatide for treatment of diabetesExclusiveWorldwideEndocrinological & MetabolicDiabetesDrug DeliveryNasal 0.35 24.00 24.00 65.00 7.00 9.00 9.00 15.00
70
TagRoyalty reduced to CL rate6/2006Cedars-Sinai Medical CenterSalix PharmaceuticalsFOIADeal 1.30 1.30 2.00 2.00 Development, LicenseRifaximin for treatment of IBSExclusiveWorldwideGastrointestinalBowel Movement Disorders, IBD - OtherDrug DeliveryOral 1.30 2.00 2.00 2.00
71
TagRoyalty reduced to CL rate5/2006Dainippon SumitomoLundbeck A/S, Chelsea TherapeuticsMid Tier PharmaFOIADeal 0.10 4.35 5.00 0.25 5.00 Equity, License, SupplyApproved, Orphan IndicationL-Threo DOPS (Droxidopa) for neurogenic orthostatic hypotension ex-Japan, Korea and ChinaExclusiveAfrica, Asia, Europe, Middle East, NAFTA, South AmericaCentral Nervous SystemOther Central Nervous SystemSyntheticsSmall Molecule 0.25 3.00 3.35 1.00 5.00 5.00 5.00 10.00
72
TagRoyalty reduced to CL rate3/2006Gilead, MyogenGlaxoSmithKlineTop PharmaFOIADeal 20.00 100.00 35.00 35.00 Co-Development, LicensePhase IIIVolibris (ambrisentan) for PAH ex-USExclusiveAfrica, Asia, Europe, Middle East, NAFTA, South AmericaCardiovascularHypertensionSyntheticsSmall Molecule 45.00 8.00 73.00 27.00 27.00 32.00 34.00
73
TagCRE to oppose CL; negotiate approprate royalty adjustments1/2006Adhera TherapeuticsProcter & GambleMid Tier PharmaFOIADeal 10.00 577.00 23.00 23.00 Co-Promotion, Development, License, Supply, TerminationPhase II, FormulationPTH1­-34 (parathyroid hormone nasal spray) for treatment of osteoporosisExclusiveWorldwideBone DiseaseOsteoporosisDrug DeliveryNasal 0.28 48.00 74.00 132.00 445.00 10.00 13.00 18.00 Cost of materials plus $0.75/Unit (see 6/06 Supply Agmt)
74
TagRoyalty in such country (or all Europe if in Europe) reduced to CL rate & thresholds for rates & sales milestones shall be adjusted down12/2005Catalyst Biosciences, TargaceptAstraZenecaTop PharmaFOIADeal 10.00 373.40 19.00 19.00 Co-Promotion, Development, License, Option, Research, TerminationPhase II, DiscoveryNeuronal nicotinic receptors, including TC-1734 for Alzheimer's and cognitive dysfunctionExclusiveWorldwideCentral Nervous System, PsychiatricAlzheimer's Disease, SchizophreniaSyntheticsSmall Molecule 26.40 0.27 165.00 172.00 373.40 11.00 11.00 12.00
$26.4M over 4 yrs | IND: $10M on Option Compound exercise, plus $75M dev/reg; POC: $42M on exercies, plus $130M dev/reg
75
TagRoyalty reduced to CL rate12/2005LillyTarganta Therapeutics, The Medicines Company, InterMune, Novartis, Melinta TherapeuticsTop Pharma, 2003-12 IPOs, 1991-2001 IPOsFOIADeal 3.00 70.00 18.00 18.00 Asset Purchase, License, RestatementApprovedOrbactiv (oritavancin) for bacterial skin infectionsExclusiveWorldwideInfectious-BacterialOther Infectious-BacterialPeptides 13.00 10.00 29.00 55.00 15.00 10.00 13.00 16.00
$2M to InterMune plus $1M to Lilly (per 12/05 Asset Agmt) | $15M to Lilly | 10-18% royalty to Lilly | $13M convertible note from Targanta to InterMune (per 12/05 Asset Agmt) | $10M to Lilly for 1st indication | $10M to LIlly for 2nd indication; $19M to InterMune (per 12/05 Asset Agmt)
76
Tag50% of all payments made by CL licensee & CL Net Sales not included in minimum annual royalty calc12/2005MaxygenRocheTop PharmaFOIADeal 8.00 104.00 37.00 37.00 Co-Development, License, Option, TerminationPreclinicalMAXY_VII (recombinant factor VIIa) for acute bleeding indicationsExclusiveWorldwideHematologicOther HematologicRecombinant DNA 0.35 52.00 44.00 104.00 28.00 30.00 34.00 27-37% in US; 20-30% in ROW
77
TagRoyalty reduced to CL rate11/2005Panion & BFAkebia Therapeutics, Keryx Biopharmaceuticals2013-20 IPOs, 1991-2001 IPOsFOIADeal 0.10 8.95 6.00 6.00 Co-Development, LicensePhase IIZerenex (ferric citrate) for hyperphosphatemia in end stage renal disease ex-Asian PacificExclusiveAfrica, Asia, Europe, Middle East, NAFTA, South AmericaRenalOther RenalSyntheticsSmall Molecule 0.35 8.50 8.95 6.00 6.00 6.00 $350K to reimb 50% of current Ph II
78
TagRoyalty reduced to CL rate9/2005Eiffel TechnologiesAllergan, AbbVie, MAP PharmaceuticalsTop Pharma, Mid Tier Pharma, 2003-12 IPOsFOIADeal 11.60 4.00 4.00 Assignment, Development, License, SupplyFormulationInhalation delivery of insulin & beta-agonist with steroidExclusiveWorldwideEndocrinological & Metabolic, RespiratoryAsthma, Chronic Obstructive Pulmonary Disease, DiabetesDrug DeliveryNasal, Other 0.60 5.75 5.25 11.60 4.00 4.00 4.00
79
TagRoyalty reduced to CL rate9/2005ev3, Covidien, Foxhollow TechnologiesMerckTop PharmaFOIADeal 6.00 52.00 3.00 3.00 License, ResearchPhase IPredictive markers for development of cardiovascular compounds & testsExclusiveWorldwideCardiovascularAtherosclerosis/Coronary Artery Disease, Hypertension, Peripheral Arterial DiseaseGenomicsPharmacogenomics 5.00 34.00 7.00 52.00 2.00 2.00 2.00 $7M for Exclusive Test
80
TagCRE to oppose CL; royalty reduced to CL rate7/2005Fennec PharmaceuticalsGlaxoSmithKlineTop PharmaFOIADeal 123.00 15.00 3.00 15.00 Development, Equity, License, OptionPhase IEniluracil for oncology ex-Europe & Africa and Exherin (ADH-1 targeting N-cadherin) WW optionExclusiveAsia, Middle East, NAFTA, South AmericaCancerBroad Focus CancerPeptides, SyntheticsSmall Molecule 3.00 60.00 63.00 60.00 13.00 14.00 15.00
13-15% royalty if GSK exercises latest take-back; otherwise, 8-9% or 11-13% on earlier take-backs | $3M, $10M or $60M in milestones on GSK take-back, depending on stage ($15M by Adherex if no take-back)
81
TagRoyalty reduced to CL rate, calculated separately for each Licensed Product7/2005Otsuka Pharmaceutical, Avanir PharmaceuticalsAstraZenecaTop PharmaFOIADeal 10.00 389.75 11.00 11.00 Co-Promotion, License, Research, TerminationPreclinical, DiscoveryAZD2479 reverse cholesterol transport (RCT) compoundsExclusiveWorldwideCardiovascularBroad Focus Cardiovascular, HypercholesterolemiaSyntheticsSmall Molecule 9.75 0.25 110.00 70.00 199.75 190.00 5.00 5.00 5.00 14 FTEs yr1; 10-15 FTEs/yr for yrs 2-3
82
TagRoyalty reduced to CL rate6/2005Bukwang PharmaceuticalsGilead, PharmassetMajor Biotech, 2003-12 IPOsFOIADeal 6.00 30.00 14.00 14.00 LicensePhase IIIClevudine (L-FMAU) for chronic HBV in NAFTA, Europe, SA & IsraelExclusiveEurope, Middle East, NAFTA, South AmericaInfectious-ViralHepatitis BSyntheticsSmall Molecule 10.00 16.00 14.00 14.00 14.00 14.00
14% royalty (12% if licensed to one of top 100 pharma companies by sales)
83
TagCRE to oppose CL; royalty reduced to CL rate6/2005Ligand, Metabasis TherapeuticsMerckTop PharmaFOIADeal 5.00 75.80 10.00 10.00 Co-Promotion, Development, License, Option, ResearchLead MoleculeAMP-activated protein kinase for metabolic diseasesExclusiveWorldwideEndocrinological & MetabolicDiabetes, Obesity, Other Endocrinological & MetabolicScreening, SyntheticsCombinatorial 6.30 0.30 44.00 20.00 75.30 6.00 6.00 8.00
84
TagRoyalty reduced to Generic Competition rate (50% of base rate)12/2004Mitsubishi Tanabe PharmaMediciNova2003-12 IPOsFOIADeal 0.50 15.25 12.00 12.00 Co-Promotion, LicensePreclinicalMN-246 (TT-138 Beta 3 agonist) for incontinence, and metabolic diseases ex-Japan, China & AseanExclusiveAfrica, Asia, Europe, Middle East, NAFTA, South AmericaEndocrinological & Metabolic, Genitourinary/GynecologicDiabetes, Incontinence, ObesitySyntheticsSmall Molecule 12.75 13.25 2.00 6.00 8.00 9.00
85
TagRoyalty reduced to 50% of CL rate11/2004Health Protection AgencyEmergent BioSolutionsFOIADeal 3.00 3.00 LicenseRecombinant toxin fragments for treatment of illness caused by C. botulinum toxinExclusiveWorldwideInfectious-BacterialBroad Focus Infectious-Bacterial 3.00 3.00 3.00
86
TagRoyalty reduced to CL rate10/2004Kyorin PharmaceuticalMediciNova2003-12 IPOsFOIADeal 0.20 5.70 12.00 12.00 LicensePhase II, Orphan IndicationKetas (ibudilast) for multiple sclerosis ex-Japan, China, S KoreaExclusiveAfrica, Asia, Europe, Middle East, NAFTA, South AmericaCentral Nervous SystemMultiple SclerosisSyntheticsSmall Molecule 5.50 5.70 6.00 8.00 10.00 12% max in US; 9% max in ROW
87
TagRoyalty reduced to CL rate9/2004Adhera TherapeuticsMerckTop PharmaFOIADeal 5.00 376.00 16.00 16.00 Co-Promotion, Development, License, Loan, Supply, TerminationPhase IPYY3-36 (Peptide YY nasal spray) for prevention of obesityExclusiveWorldwideEndocrinological & MetabolicObesityDrug Delivery, PeptidesNasal 30.00 131.00 166.00 210.00 9.00 10.00 11.00 up to $30M loan for expansion of production capacity
88
TagRoyalty reduced to CL rate8/2004Euthymics Bioscience, DOV PharmaceuticalMerckTop PharmaFOIADeal 35.00 480.00 20.00 20.00 Co-Promotion, Development, License, TerminationPhase IDOV 21947 & 216303 for depression, anxiety and addictionExclusiveWorldwidePsychiatricAddiction, Anxiety, Depression & ManiaSyntheticsSmall Molecule 185.00 140.00 360.00 120.00 11.00 11.00 12.00
89
TagRoyalty reduced to CL rate7/2004Cleveland ClinicCleveland BioLabs2003-12 IPOsSEC FullDeal 8.00 2.00 2.00 Equity, LicenseDiscoveryDifferential modulation cell death / survival mechanisms of cancer cellsExclusiveWorldwideCancerBroad Focus CancerGenomics, ScreeningGene Expression 1.50 6.50 8.00 2.00 2.00 2.00 $1.5M for biodefense uses | $6.5M for all other uses
90
TagRoyalty reduced to CL rate6/2004AlnylamMerckTop PharmaFOIADeal 3.00 33.50 50.00 15.00 Co-Development, Co-Promotion, License, Research, TerminationDiscoveryRNAi VEGF for ocular diseasesExclusiveWorldwideOphthalmicBroad Focus OphthalmicOligonucleotidesRNAi 0.49 30.50 33.50 11.00 12.00 13.00 50.00
91
TagRoyalty reduced to CL rate so long as CL sales exceed 25% of total sales in such country6/2004Nektar TherapeuticsAllergan, AbbVie, MAP PharmaceuticalsTop Pharma, Mid Tier Pharma, 2003-12 IPOsFOIADeal 4.00 5.00 5.00 LicensePreclinical, FormulationSEDS Inhalation technology for dihydroergotamine mesylate for migraineExclusiveWorldwideCentral Nervous SystemMigraineDrug DeliveryNasal 0.30 4.00 4.00 3.00 3.00 4.00
92
TagRoyalty reduced to CL rate, but no lower than Know-how rate (66% of base rate)5/2004Inovio PharmaceuticalsMerckTop PharmaFOIADeal 1.00 38.75 5.00 5.00 License, Option, Research, SupplyFormulation, DeviceMedPulser electroporation delivery of CEA or HER2/neu for DNA Vaccines for infection & oncologyNon-exclusiveWorldwideCancer, Infectious-Bacterial, Infectious-ViralBroad Focus Cancer, Broad Focus Infectious-Bacterial, Broad Focus Infectious-ViralDevice, Drug DeliveryTransdermal 0.25 17.00 20.75 38.75 3.00 4.00 5.00
93
TagRoyalty reduced to Generic Competition rate (50% of base rate)4/2004Mitsubishi Tanabe PharmaMediciNova2003-12 IPOsFOIADeal 1.00 19.75 12.00 12.00 Co-Promotion, LicensePhase IMN-305 (serotonin ra) for anxiety ex-Japan, China & AseanExclusiveAfrica, Asia, Europe, Middle East, NAFTA, South AmericaPsychiatricAnxietySyntheticsSmall Molecule 11.75 12.75 7.00 7.00 9.00 11.00
94
TagRoyalty reduced to CL rate3/2004Oncternal Therapeutics, GTxJohnson & Johnson, Ortho BiotechTop PharmaFOIADeal 6.00 127.00 18.00 18.00 Co-Promotion, Development, LicensePhase IAndarine SARM (Selective Androgen Receptor Modulator) for cancer-induced cachexiaExclusiveWorldwideCancer, Endocrinological & MetabolicBroad Focus Cancer, Other Endocrinological & MetabolicSyntheticsSmall Molecule 0.23 37.00 84.00 127.00 9.00 11.00 13.00 25.00
25% Additional Royalty on sales by GTx to Urologists in the US from Co-promotion
95
TagRoyalty reduced to CL rate2/2004Kissei PharmaceuticalMediciNova2003-12 IPOsFOIADeal 18.00 8.00 8.00 Co-Promotion, License, SupplyPhase IIMN-221 (KUR-1246) to treat premature labor ex-JapanExclusiveAfrica, Asia, Europe, Middle East, NAFTA, South AmericaGenitourinary/GynecologicOther Genitourinary/GynecologicSyntheticsSmall Molecule 18.00 18.00 8.00 8.00 8.00
96
TagCRE to oppose CL; royalty reduced to CL rate12/2003Ligand, Metabasis TherapeuticsMerckTop PharmaFOIADeal 0.50 62.88 9.00 9.00 License, Option, ResearchDiscovery, FormulationHepDirect prodrug technology for HCV compoundsExclusiveWorldwideInfectious-ViralHepatitis CDrug Delivery, Screening, SyntheticsOther, Small Molecule 1.38 0.28 25.00 36.00 62.88 7.00 7.00 7.00
97
TagRoyalty reduced to CL rate11/2003AVEO PharmaceuticalsMerckTop PharmaFOIADeal 9.25 62.80 7.00 5.00 7.00 Equity, License, ResearchDiscoveryTumor maintenance genes as small molecule oncology targetsExclusiveWorldwideCancerBroad Focus CancerGenomics, ScreeningGene Expression 5.00 6.00 0.30 42.55 62.80 5.00 6.00 6.00 $5M eq at time of 4/05 restated agmt
98
TagRoyalty reduced to CL rate11/2003Ligand, NeurogenMerckTop PharmaFOIADeal 22.00 344.80 12.00 15.00 12.00 Equity, License, Research, TerminationLead Molecule, DiscoveryNovel modulators of Vanilloid Receptors (VR1) for Pain & IncontinenceExclusiveWorldwideCentral Nervous System, Genitourinary/GynecologicIncontinence, PainRecombinant DNA 15.00 9.80 0.28 118.00 155.00 319.80 25.00 10.00 10.00 11.00
99
TagRoyalty reduced to 50% of CL rate10/2003AbgenixAstraZenecaTop PharmaFOIADeal 151.00 12.00 100.00 12.00 Co-Development, Equity, License, Option, ResearchDiscoveryFully human monoclonal antibodies to UPAR and add'l targets for cancerExclusiveWorldwideCancerBroad Focus CancerMonoclonalsHuman Abs 100.00 60.00 51.00 211.00 8.00 9.00 11.00 18.00
8-12% for Proprietary ABX Antigens; 6-10% for Non-Proprietary | $100M in preferred, convertible at $30/Sh
100
TagRoyalty reduced to Generic Product rate (50% of base rate if 30%+ unit share, 80% of base if 15-30% units)10/2003AnesivaBristol-Myers SquibbTop PharmaFOIADeal 25.00 570.00 50.00 20.00 Co-Development, Co-Promotion, Equity, LicensePhase IIIE2F Decoy transcription factor for restenosis & atherosclerosisExclusiveWorldwideCardiovascularAtherosclerosis/Coronary Artery Disease, RestenosisTranscription Factors 20.00 108.50 96.50 250.00 320.00 14.00 15.00 17.00 50.00